Acutaas Chemicals Peer Comparison

NSE: ACUTAAS | BSE: 543349

₹3,281.60

₹-47.60 (-1.43%)

As on 28-Aug-2026IST

Market cap

₹26,871 Cr

Revenue (TTM)

₹1,462 Cr

P/E Ratio

69.6

P/B Ratio

15.5

Div. Yield

0.1 %

Edit

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Market cap (₹ Cr)	26,871	32,104	29,892	29,103	20,739
Revenue (₹ Cr)	1,462	3,564	1,936	9,205	5,632
Net Profit (₹ Cr)	387.35	414.00	288.22	-371.81	662.35
Net Margin (%)	26.01	11.23	14.79	-3.93	11.75
RoE (%)	25.18	8.38	29.77	-3.85	14.34
Price to Earnings	69.57	78.49	103.71	--	31.31
Price-To-Book	15.55	6.38	22.27	3.64	4.23

Income Statement (₹ Cr)

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Operating Revenue	1,461.80	3,564.00	1,935.80	9,205.28	5,632.31
Total Income	1,489.25	3,686.00	1,948.58	9,449.59	5,638.56
Total Expenditure	919.25	2,792.00	1,485.56	8,195.15	4,354.97
EBITDA	542.56	772.00	450.24	1,010.13	1,277.34
Depreciation	37.68	226.00	50.83	857.51	306.94
EBIT	504.88	546.00	399.41	152.62	970.39
Interest	3.77	217.00	40.84	342.73	111.70
Other Income	27.45	122.00	12.78	244.31	6.25
Exceptional Items	0.00	12.00	0.00	-216.88	15.92
Profit before Tax	528.56	463.00	371.35	-162.68	880.86
Provision for Tax	141.21	49.00	83.14	209.13	218.51
Profit after Tax	387.35	414.00	288.22	-371.81	662.35

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Shareholder's Funds	1,653.56	4,940.00	1,288.82	8,162.62	5,085.00
Minority Interest	-1.13	-5.00	0.00	0.00	0.00
Non-Current Liabilities	42.40	1,712.00	202.03	5,044.14	542.92
Current Liabilities	230.82	1,622.00	835.87	4,758.28	2,092.03
Total Liabilities	1,549.26	8,100.00	1,451.43	15,513.53	6,221.20

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Non-Current Assets	1,026.85	5,343.00	519.60	10,211.52	3,533.26
Current Assets	881.27	2,606.00	1,681.81	7,191.66	3,767.65
Total Assets	1,549.26	8,100.00	1,451.43	15,513.53	6,221.20
Total Debt*	8.18	1,859.00	393.17	4,720.27	1,285.79
Net Current Assets	650.46	984.00	845.94	2,433.38	1,675.62
Contingent Liabilities	15.38	770.26	12.25	99.76	3.04

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Cash From Operating Activities	118.34	-22.00	159.18	892.30	866.57
Cash Flow from Investing Activities	-223.94	-783.00	-64.81	-477.46	-691.29
Cash from Financing Activities	261.12	409.00	-39.81	-440.83	-92.51
Net Cash Inflow / Outflow	155.52	-396.00	54.56	-25.99	82.77

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
ROCE (%)	20.14	4.07	26.97	6.61	16.16
ROE (%)	25.18	8.38	29.77	-3.85	14.34
ROA (%)	21.93	4.94	24.77	-2.21	9.48
EBIT Margin (%)	34.54	15.32	20.63	1.66	17.23
Net Margin (%)	26.01	11.23	14.79	-3.93	11.75
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Revenue Growth (%)	40.90	18.37	46.65	0.78	24.83
EBIT Growth (%)	124.50	252.26	62.13	-70.53	40.39
Net Profit Growth (%)	104.15	377.85	89.49	-1,383.43	38.13
EPS Growth (%)	42.32	1,001.33	78.60	-484.84	34.88
Book Value Growth (%)	94.96	29.77	42.49	2.28	15.42

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Price / Earnings	69.57	80.56	102.12	-93.01	31.61
Price / Book Value	15.55	6.38	22.27	3.64	4.23
Dividend Yield (%)	0.08	0.00	0.08	0.00	0.21
EV/EBITDA	49.08	43.48	66.20	32.91	16.54
Market Cap (₹ Cr)	19,988.69	23,064.69	0.00	29,731.27	11,813.97

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Debt to Equity	0.01	0.31	0.11	0.53	0.06
Short term debt to equity ratio	0.02	0.11	0.54	0.12	0.25
Current Ratio	3.82	1.61	2.01	1.51	1.80
Quick Ratio	2.82	1.06	1.14	0.87	1.00
Interest Coverage	141.16	3.13	10.09	0.53	8.89

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Debtors to sales (%)	24.80	16.50	26.28	23.44	16.15
Asset Turnover	0.83	0.43	1.66	0.55	0.81
Receivable days	90.06	60.36	47.59	77.05	47.23
Inventory Days	61.02	64.42	62.58	77.13	64.75
Payable days	96.06	218.94	228.78	173.49	156.05
Cash Conversion Cycle	55.02	-94.15	-118.62	-19.30	-44.08

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.